Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/taylor-francis/thromboembolic-prophylaxis-in-orthopedic-surgery-using-dabigatran-an-6x6izN1YfC
References (14)
-
B. Eriksson, O. Dahl, N. Rosencher, A. Kurth, C. Dijk, S. Frostick, P. Kälebo, A. Christiansen, S. Hantel, Rohan Hettiarachchi, J. Schnee, H. Büller (2007)
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trialJournal of Thrombosis and Haemostasis, 5
-
J. Stangier (2008)
Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran EtexilateClinical Pharmacokinetics, 47
-
B. Eriksson, O. Dahl, M. Huo, A. Kurth, S. Hantel, K. Hermansson, J. Schnee, R. Friedman (2011)
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)Thrombosis and Haemostasis, 105
-
B. Eriksson, O. Dahl, H. Büller, Rohan Hettiarachchi, N. Rosencher, Bravo Ml, L. Ahnfelt, F. Piovella, J. Stangier, P. Kälebo, P. Reilly (2005)
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trialJournal of Thrombosis and Haemostasis, 3
-
J. Heit (2001)
Prevention of venous thromboembolism.Clinics in geriatric medicine, 17 1
-
Sunny Kim (2008)
Changes in surgical loads and economic burden of hip and knee replacements in the US: 1997-2004.Arthritis and rheumatism, 59 4
-
S. Connolly, M. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P. Reilly, E. Themeles, Jeanne Varrone, Susan Wang, M. Alings, D. Xavier, Jun Zhu, R. Diaz, B. Lewis, H. Darius, H. Diener, C. Joyner, L. Wallentin (2009)
Dabigatran versus warfarin in patients with atrial fibrillation.The New England journal of medicine, 361 12
-
William Geerts, David Bergqvist, G. Pineo, John Heit, Charles Samama, Michael Lassen, Clifford Colwell (2008)
Prevention of Venous Thromboembolism* American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition)Chest, 133
-
J. Stangier, H. Stähle, K. Rathgen, W. Roth, K. Shakeri‐Nejad (2008)
Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic ImpairmentThe Journal of Clinical Pharmacology, 48
-
J. Heit, M. Silverstein, D. Mohr, T. Petterson, L. Melton (1999)
Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study.Archives of internal medicine, 159 5
-
S. Schulman, C. Kearon, A. Kakkar, P. Mismetti, S. Schellong, H. Eriksson, David Baanstra, J. Schnee, S. Goldhaber (2009)
Dabigatran versus warfarin in the treatment of acute venous thromboembolism.The New England journal of medicine, 361 24
-
Jeffrey Ginsberg, B. Davidson, P. Comp, C. Francis, R. Friedman, M. Huo, J. Lieberman, J. Muntz, G. Raskob, M. Clements, S. Hantel, J. Schnee, J. Caprini (2009)
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.The Journal of arthroplasty, 24 1
-
B. Eriksson, O. Dahl, N. Rosencher, A. Kurth, Niek Dijk, S. Frostick, M. Prins, Rohan Hettiarachchi, S. Hantel, J. Schnee, H. Büller (2007)
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trialThe Lancet, 370
-
B. Eriksson, O. Dahl, L. Ahnfelt, P. Kälebo, J. Stangier, G. Nehmiz, K. Hermansson, V. Kohlbrenner (2004)
Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO IJournal of Thrombosis and Haemostasis, 2
- Publisher
- Taylor & Francis
- Copyright
- © Expert Reviews Ltd
- ISSN
- 1744-8344
- eISSN
- 1477-9072
- DOI
- 10.1586/erc.12.15
- pmid
- 22458575
- Publisher site
- See Article on Publisher Site
Abstract
Dabigatran etexilate is a direct thrombin inhibitor that has been in clinical use for the prevention and treatment of venous and arterial thrombosis. Dabigatran allows for oral administration, has a rapid onset of action and has a predictable anticoagulant effect. Studies in healthy volunteers and in patients undergoing orthopedic surgery indicate that dabigatran has a predictable pharmacokinetic profile, allowing for a fixed-dose regimen without the need for coagulation monitoring. Dabigatran is approved in the EU and Canada for prophylaxis of thromboembolism in patients undergoing total hip and knee arthroplasties. The focus of this article is on the clinical data of using dabigatran as venous thromboprophylaxis in orthopedic surgery patients.
Journal
Expert Review of Cardiovascular Therapy – Taylor & Francis
Published: Apr 1, 2012
Keywords: bleeding; clinical trial; DVT; orthopedic surgery; PE; total joint replacement; venous thromboembolism